116 related articles for article (PubMed ID: 34884681)
21. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
Meier-Schiesser B; Mellett M; Ramirez-Fort MK; Maul JT; Klug A; Winkelbeiner N; Fenini G; Schafer P; Contassot E; French LE
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884681
[TBL] [Abstract][Full Text] [Related]
22. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
[TBL] [Abstract][Full Text] [Related]
23. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Gooderham M; Papp K
BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
25. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
[TBL] [Abstract][Full Text] [Related]
26. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Schafer P
Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
[TBL] [Abstract][Full Text] [Related]
27. Nod-Like Receptors in Host Defence and Disease at the Epidermal Barrier.
Danis J; Mellett M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925158
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
29. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
30. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
31. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
32. Evidence for a role of autoinflammation in early-phase psoriasis.
Fanoni D; Venegoni L; Vergani B; Tavecchio S; Cattaneo A; Leone BE; Berti E; Marzano AV
Clin Exp Immunol; 2019 Dec; 198(3):283-291. PubMed ID: 31509228
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Li H; Fan C; Feng C; Wu Y; Lu H; He P; Yang X; Zhu F; Qi Q; Gao Y; Zuo J; Tang W
Br J Pharmacol; 2019 Jul; 176(13):2209-2226. PubMed ID: 30883697
[TBL] [Abstract][Full Text] [Related]
34. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis.
Germán B; Wei R; Hener P; Martins C; Ye T; Gottwick C; Yang J; Seneschal J; Boniface K; Li M
JCI Insight; 2019 Jan; 4(2):. PubMed ID: 30674716
[TBL] [Abstract][Full Text] [Related]
35. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Reich K; Papp KA; Armstrong AW; Wasfi Y; Li S; Shen YK; Randazzo B; Song M; Kimball AB
Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]